Burosumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | FGF 23 |
| Clinical data | |
| Trade names | Crysvita |
| Other names | KRN23 |
| ATC code | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6388H9904N1700O2006S46 |
| Molar mass | 144.1 kDa g·mol−1 |
Burosumab (INN, trade name Crysvita) known as KRN23 is a human monoclonal antibody designed for the treatment of X-linked hypophosphatemia.[1][2][3] Burosumab was approved by the FDA for its intended purpose, in patients aged 1 year and older, on 17 April 2018.[4] The FDA approval fell under both the breakthrough therapy and orphan drug designations.[4]
This drug was developed by Ultragenyx and is in a collaborative license agreement with Kyowa Hakko Kirin.[5]
While burosumab is effective for the treatment of X-linked hypophosphatemia, the UK National Institute for Health and Care Excellence has raised concerns regarding the incremental cost-effectiveness of the new treatment.[6]
References
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Burosumab, American Medical Association.[permanent dead link]
- ^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2): 255.
- ^ "Burosumab (KRN23) for X-Linked Hypophosphatemia (XLH)" (PDF). n.d. Retrieved 2018-04-18.
- ^ a b "FDA approves first therapy for rare inherited form of rickets, x-linked hypophosphatemia" (Press release). FDA. 17 April 2018.
- ^ "Collaboration with Ultragenyx to Develop and Commercialize KRN23 for X-linked Hypophosphatemia" (Press release). Kyowa Kirin. 4 September 2013. Retrieved 2018-04-17.
- ^ "U.K. cost watchdogs turn away rare disease med Crysvita".
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |